ES2654109T3 - Combinación de agentes antivirales de acción directa y ribavirina para tratar pacientes con el VHC - Google Patents

Combinación de agentes antivirales de acción directa y ribavirina para tratar pacientes con el VHC Download PDF

Info

Publication number
ES2654109T3
ES2654109T3 ES14725812.3T ES14725812T ES2654109T3 ES 2654109 T3 ES2654109 T3 ES 2654109T3 ES 14725812 T ES14725812 T ES 14725812T ES 2654109 T3 ES2654109 T3 ES 2654109T3
Authority
ES
Spain
Prior art keywords
daas
treatment
patient
compound
ribavirin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14725812.3T
Other languages
English (en)
Spanish (es)
Inventor
Barry M. Bernstein
Sandeep Dutta
Wei Liu
Thomas J. PODSADECKI
Andrew L. Campbell
Rajeev M. Menon
Chih-Wei Lin
Tianli WANG
Walid M. Awni
Sven MENSING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2654109(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Application granted granted Critical
Publication of ES2654109T3 publication Critical patent/ES2654109T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14725812.3T 2013-03-14 2014-03-14 Combinación de agentes antivirales de acción directa y ribavirina para tratar pacientes con el VHC Active ES2654109T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14
US201361783437P 2013-03-14
PCT/US2014/027556 WO2014152635A1 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Publications (1)

Publication Number Publication Date
ES2654109T3 true ES2654109T3 (es) 2018-02-12

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14725812.3T Active ES2654109T3 (es) 2013-03-14 2014-03-14 Combinación de agentes antivirales de acción directa y ribavirina para tratar pacientes con el VHC

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP3318258B1 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR20180045055A (enExample)
CN (3) CN109908353A (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA030482B1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T4 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG11201507361YA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TWI678205B (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3318258B1 (en) 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients
CN105658219A (zh) * 2013-10-25 2016-06-08 艾伯维公司 用于治疗hcv的方法
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
CA2943054A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP3383662B1 (en) 2016-01-08 2020-09-02 Entrust Datacard Corporation Card printing mechanism with card return path
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
MA46292A (fr) * 2016-09-23 2019-07-31 Abbvie Inc Réglage de dose
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
CN112351799A (zh) * 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522862A (ja) * 2008-06-10 2011-08-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EP2853531A3 (en) * 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
TWI523658B (zh) * 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
EP3318258B1 (en) 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Also Published As

Publication number Publication date
JP6563894B2 (ja) 2019-08-21
CY1121474T1 (el) 2020-05-29
PL2968302T3 (pl) 2018-04-30
WO2014152635A9 (en) 2014-12-11
EP3318258B1 (en) 2020-05-13
CA2901818C (en) 2021-05-04
EP2968302A1 (en) 2016-01-20
LT2968302T (lt) 2017-12-27
EP3733180A1 (en) 2020-11-04
IL267927A (en) 2019-09-26
SG11201507361YA (en) 2015-10-29
SG10201709840UA (en) 2018-01-30
WO2014152635A1 (en) 2014-09-25
EP2968302B1 (en) 2017-09-06
TW202002979A (zh) 2020-01-16
CN109908353A (zh) 2019-06-21
DK2968302T3 (en) 2017-12-18
ZA201705080B (en) 2019-02-27
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
EA201890507A1 (ru) 2018-07-31
MX2015012536A (es) 2016-01-12
HUE036069T2 (hu) 2018-06-28
CN108187056A (zh) 2018-06-22
CN105007921B (zh) 2018-12-11
KR20180045055A (ko) 2018-05-03
JP2019167347A (ja) 2019-10-03
NO3090119T3 (enExample) 2018-03-31
HK1213191A1 (en) 2016-06-30
EA030482B1 (ru) 2018-08-31
US20140274934A1 (en) 2014-09-18
JP2019214585A (ja) 2019-12-19
AU2018202581A1 (en) 2018-05-10
AU2020201656A1 (en) 2020-03-26
HRP20171898T1 (hr) 2018-04-06
RS56735B1 (sr) 2018-03-30
BR112015020918A2 (pt) 2017-07-18
IL240445A0 (en) 2015-09-24
JP2016513703A (ja) 2016-05-16
AU2014239322A1 (en) 2015-08-27
SMT201800017T1 (it) 2018-03-08
IL240445B (en) 2019-07-31
KR101853605B1 (ko) 2018-05-03
EA201591701A1 (ru) 2016-02-29
EP3318258A1 (en) 2018-05-09
CN105007921A (zh) 2015-10-28
PL2968302T4 (pl) 2018-04-30
TW201505633A (zh) 2015-02-16
KR20150129035A (ko) 2015-11-18
CA2901818A1 (en) 2014-09-25
AU2014239322B2 (en) 2018-04-05
SI2968302T1 (en) 2018-04-30
AU2018202581B2 (en) 2019-12-05
EP3915559A1 (en) 2021-12-01
EP2968302B9 (en) 2019-02-13
HK1255257A1 (en) 2019-08-09

Similar Documents

Publication Publication Date Title
ES2824473T3 (es) Combinación de dos antivirales para el tratamiento de la hepatitis C
AU2018202581B2 (en) Combination of direct acting antiviral agents and ribavirin for treating HCV patients
AU2015240754B2 (en) Methods for treating HCV
JP2019214578A (ja) Ｈｃｖを処置するための方法
HK40037284A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
HK1244668B (en) Combination of two antivirals for treating hepatitis c
HK1223817B (en) Combination of two antivirals for treating hepatitis c
HK1213191B (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients